Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 6/20 | 0.45 |
| ▸ | CTSS | P25774 | 4/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21873981 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2463121 | 1.00 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL30759429 | 0.89 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL29727304 | 0.89 | CYP1A2 (0.47) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2721300 | 0.88 | CYP1A2 (0.68) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2721298 | 0.88 | CYP1A2 (0.68) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL2301394 | 0.88 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL3242610 | 0.88 | CYP1A2 (0.60) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL14649972 | 0.88 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 | |
| SCHEMBL475730 | 0.88 | CYP1A2 (0.46) | CYP1A2CYP2C9CYP2C19HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) | 2025-06-12 | — | — | US | disclosed |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) | 2024-12-17 | — | — | US | disclosed |
| EP-3514158-B1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-05-19 | — | — | US | disclosed |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2022-05-19 | — | — | US | disclosed |
| US-11274100-B2 | EP300/CREBBP inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-03-15 | — | — | US | disclosed |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-08-03 | — | — | US | disclosed |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-06-10 | — | — | US | disclosed |
| US-20210155632-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2021-05-27 | — | — | US | disclosed |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2015-12-24 | — | — | US | disclosed |
| US-9212168-B2 | Hepatitis C virus inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-15 | — | — | US | disclosed |
| EP-2951182-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | Aptinyx Inc. (US) | 2015-12-09 | — | — | EP | disclosed |
| CN-102884059-B | N-acyl cyclic amine derivatives or pharmaceutically acceptable salts thereof | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2015-08-26 | — | — | CN | disclosed |
| WO-2014120784-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120783-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120786-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| WO-2014120784-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | NAUREX, INC. (US) | 2014-08-07 | — | — | WO | disclosed |
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130115194-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, HDGF | CYP1A2 275/4885CYP2C9 197/4885CYP2C19 377/4885 |
| US-11274100-B2 | EP300/CREBBP inhibitor | EP300, CREBBP, CREB1 | CYP1A2 4354/4885CYP2C9 4710/4885CYP2C19 4431/4885 |
| US-20250186392-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CYP1A2 3815/4885CYP2C9 1515/4885CYP2C19 1345/4885 |
| US-12167998-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | CYP1A2 3815/4885CYP2C9 1515/4885CYP2C19 1345/4885 |
| US-20150368253-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CYP1A2 3815/4885CYP2C9 1515/4885CYP2C19 1345/4885 |
| US-20220151992-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CYP1A2 3815/4885CYP2C9 1515/4885CYP2C19 1345/4885 |
| US-20210171520-A1 | EP300/CREBBP INHIBITOR | EP300, CREBBP, CREB1 | CYP1A2 4354/4885CYP2C9 4710/4885CYP2C19 4431/4885 |
| US-20210155632-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CYP1A2 3815/4885CYP2C9 1515/4885CYP2C19 1345/4885 |
| US-20150368252-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | CYP1A2 4025/4885CYP2C9 2847/4885CYP2C19 2632/4885 |
| US-11077094-B2 | Spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN3A | CYP1A2 3815/4885CYP2C9 1515/4885CYP2C19 1345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.